155 related articles for article (PubMed ID: 11451568)
1. Intracellular and extracellular control of activin function by novel regulatory molecules.
Tsuchida K; Matsuzaki T; Yamakawa N; Liu Z; Sugino H
Mol Cell Endocrinol; 2001 Jun; 180(1-2):25-31. PubMed ID: 11451568
[TBL] [Abstract][Full Text] [Related]
2. Novel factors in regulation of activin signaling.
Tsuchida K; Nakatani M; Matsuzaki T; Yamakawa N; Liu Z; Bao Y; Arai KY; Murakami T; Takehara Y; Kurisaki A; Sugino H
Mol Cell Endocrinol; 2004 Oct; 225(1-2):1-8. PubMed ID: 15451561
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family.
Tsuchida K; Arai KY; Kuramoto Y; Yamakawa N; Hasegawa Y; Sugino H
J Biol Chem; 2000 Dec; 275(52):40788-96. PubMed ID: 11010968
[TBL] [Abstract][Full Text] [Related]
4. Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function.
Bartholin L; Maguer-Satta V; Hayette S; Martel S; Gadoux M; Corbo L; Magaud JP; Rimokh R
Oncogene; 2002 Mar; 21(14):2227-35. PubMed ID: 11948405
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a PDZ protein that interacts with activin type II receptors.
Shoji H; Tsuchida K; Kishi H; Yamakawa N; Matsuzaki T; Liu Z; Nakamura T; Sugino H
J Biol Chem; 2000 Feb; 275(8):5485-92. PubMed ID: 10681527
[TBL] [Abstract][Full Text] [Related]
6. Characterization of isoforms of activin receptor-interacting protein 2 that augment activin signaling.
Liu ZH; Tsuchida K; Matsuzaki T; Bao YL; Kurisaki A; Sugino H
J Endocrinol; 2006 May; 189(2):409-21. PubMed ID: 16648306
[TBL] [Abstract][Full Text] [Related]
7. Expression of FLRG, a novel activin A ligand, is regulated by TGF-beta and during hematopoiesis [corrected].
Maguer-Satta V; Bartholin L; Jeanpierre S; Gadoux M; Bertrand S; Martel S; Magaud JP; Rimokh R
Exp Hematol; 2001 Mar; 29(3):301-8. PubMed ID: 11274757
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer.
Tsuchida K; Nakatani M; Uezumi A; Murakami T; Cui X
Endocr J; 2008 Mar; 55(1):11-21. PubMed ID: 17878607
[TBL] [Abstract][Full Text] [Related]
9. FLRG, member of the follistatin family, a new player in hematopoiesis.
Maguer-Satta V; Rimokh R
Mol Cell Endocrinol; 2004 Oct; 225(1-2):109-18. PubMed ID: 15451575
[TBL] [Abstract][Full Text] [Related]
10. The activin binding proteins follistatin and follistatin-related protein are differentially regulated in vitro and during cutaneous wound repair.
Wankell M; Kaesler S; Zhang YQ; Florence C; Werner S; Duan R
J Endocrinol; 2001 Dec; 171(3):385-95. PubMed ID: 11739004
[TBL] [Abstract][Full Text] [Related]
11. Evidence for an inhibitory role of bone morphogenetic protein(s) in the follicular-luteal transition in cattle.
Kayani AR; Glister C; Knight PG
Reproduction; 2009 Jan; 137(1):67-78. PubMed ID: 18936084
[TBL] [Abstract][Full Text] [Related]
12. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin.
Sidis Y; Tortoriello DV; Holmes WE; Pan Y; Keutmann HT; Schneyer AL
Endocrinology; 2002 May; 143(5):1613-24. PubMed ID: 11956142
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the inhibition of activin signalling by follistatin.
Harrington AE; Morris-Triggs SA; Ruotolo BT; Robinson CV; Ohnuma S; Hyvönen M
EMBO J; 2006 Mar; 25(5):1035-45. PubMed ID: 16482217
[TBL] [Abstract][Full Text] [Related]
14. Genomic organization and promoter analysis of mouse follistatin-related gene (FLRG).
Nakatani M; Yamakawa N; Matsuzaki T; Shimasaki S; Sugino H; Tsuchida K
Mol Cell Endocrinol; 2002 Mar; 189(1-2):117-23. PubMed ID: 12039070
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the activin-inhibin-follistatin system by bone morphogenetic proteins in the zebrafish ovary.
Li CW; Ge W
Biol Reprod; 2013 Sep; 89(3):55. PubMed ID: 23843234
[TBL] [Abstract][Full Text] [Related]
16. Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells.
Rejon CA; Hancock MA; Li YN; Thompson TB; Hébert TE; Bernard DJ
Cell Signal; 2013 Dec; 25(12):2717-26. PubMed ID: 24018044
[TBL] [Abstract][Full Text] [Related]
17. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.
Yamashita H; ten Dijke P; Huylebroeck D; Sampath TK; Andries M; Smith JC; Heldin CH; Miyazono K
J Cell Biol; 1995 Jul; 130(1):217-26. PubMed ID: 7790373
[TBL] [Abstract][Full Text] [Related]
18. Purification of recombinant activin A using the second follistatin domain of follistatin-related gene (FLRG).
Arai KY; Tsuchida K; Li C; Watanabe G; Sugino H; Taya K; Nishiyama T
Protein Expr Purif; 2006 Sep; 49(1):78-82. PubMed ID: 16737827
[TBL] [Abstract][Full Text] [Related]
19. Activin and bone morphogenetic protein (BMP) signalling during tooth development.
Heikinheimo K; Bègue-Kirn C; Ritvos O; Tuuri T; Ruch JV
Eur J Oral Sci; 1998 Jan; 106 Suppl 1():167-73. PubMed ID: 9541221
[TBL] [Abstract][Full Text] [Related]
20. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.
Sidis Y; Mukherjee A; Keutmann H; Delbaere A; Sadatsuki M; Schneyer A
Endocrinology; 2006 Jul; 147(7):3586-97. PubMed ID: 16627583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
